Celgene COO Scott Smith exits suddenly in wake of MS fumble, Otezla shortfall
admin 3rd April 2018 Uncategorised 0In the past year, Celgene received a refuse-to-file letter from the FDA on its MS candidate ozanimod, pulled the plug on another phase 3 immunology study and missed sales estimates as its psoriasis med Otezla fell short. So the departure of COO Scott Smith—former chief of the company’s immunology business—wasn’t entirely surprising.
More: Celgene COO Scott Smith exits suddenly in wake of MS fumble, Otezla shortfall
Source: fierce